Skip to content

Overall survival of patients with metastatic castrate resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function

This presentation reports a real-world study that examines patient characteristics and survival outcomes among patients with metastatic castration-resistant prostate cancer assessed for PTEN loss of function status via genomic testing. This study used data from the nationwide, de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database from approximately 280 US cancer clinics.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically